Summary
The plasma kinetics of platinum after i.v. bolus administration of cisplatin was determined for 17 patients with advanced cancer. Statistical analysis of individual values revealed a high correlation between the area under the plasma concentration-time curve (AUC) of free platinum (unbound to proteins) and the concentration of platinum bound to plasma proteins 24 h after drug administration (Cp24). A similar correlation was found between the peak plasma values of ultrafiltrable platinum (Cp0) and Cp24. When studied in the same patient, increases in free platinum AUC and Cp0 were also found to result in increased Cp24. It is suggested that a single measurement of plasma platinum concentration 24 h after i.v. infusion of cisplatin could be a simple method either of detecting patients with extreme values of AUC and Cp0 or of studying the evolution of these parameters during multiple courses of treatment, although it cannot be used to give precise values for AUC and Cp0.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Balis FM, Holcenberg JS, Bleyer WA (1983) Clinical pharmacokinetics of commonly used anticancer drugs. Clin Pharmacokinet 8: 202
Campbell AB, Kalman SM, Jacobs C (1983) Plasma platinum levels: relationship to cisplatin dose and nephrotoxicity. Cancer Treat Rep 67: 169
Daley-Yates PT, McBrien DCH (1984) Cisplatin metabolites in plasma, a study of their pharmacokinetics and importance in the nephrotoxic and antitumour activity of cisplatin. Biochem Pharmacol 33: 3063
Gormley PE, Bull JM, LeRoy AF, Cysyk R (1979) Kinetics of cis-dichlorodiammine-platinum. Clin Pharmacol Ther 25: 351
Gullo JJ, Litterst CL, Maguire PJ, Sikic BI, Hoth DF, Wooley PV (1980) Pharmacokinetics and protein binding of cis-dichlorodiammine platinum (II) administered as a one-hour or as a twenty-hour infusion. Cancer Chemother Pharmacol 5: 21
Hecquet B, Adenis L, Demaille A (1983) In vitro interactions of TN06 with human plasma. Cancer Chemother Pharmacol 11: 177
Himmelstein KJ, Patton TF, Belt RJ, Taylor S, Repta AJ, Sternson LA (1981) Clinical kinetics of intact cisplatin and some related species. Clin Pharmacol Ther 29: 658
Leroy AF, Wehling ML, Sponseller HL, Litterst CL, Gram TE, Guarino AM, Becher DA (1977) Analysis of platinum in biological materials by flameless atomic absorption spectrophotometry. Biochem Med 18: 184
Meites L (1983) The general non-linear regression program CFT 4A. Clarkson College of Technology, Potsdam, NY
Powis G (1985) Anticancer drug pharmacodynamics. Cancer Chemother Pharmacol 14: 177
Takahashi K, Seki T, Nishikawa K, Minamide S, Iwabuchi M, Ono M, Nagamine S, Horinishi H (1985) Antitumor activity and toxicity of serum protein-bound platinum formed from cisplatin. Jpn J Cancer Res 76: 68
Vermorken JB, Van der Vijgh WJF, Klein I, Gall HE, Pinedo HM (1982) Pharmacokinetics of free platinum species following rapid, 3-hr and 24-hr infusions of cis-diamminedichloroplatinum (II) and its therapeutic implications. Eur J Cancer Clin Oncol 18: 1069
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fournier, C., Vennin, P. & Hecquet, B. Correlation between free platinum AUC and total platinum measurement 24 h after i.v. bolus injection of cisplatin in humans. Cancer Chemother. Pharmacol. 21, 75–77 (1988). https://doi.org/10.1007/BF00262745
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00262745